H2S confers colonoprotection against TNBS-induced colitis by HO-1 upregulation in rats
- 02.08.2017
- Original Article
- Verfasst von
- Krisztina Kupai
- Nikoletta Almási
- Magdolna Kósa
- János Nemcsók
- Zsolt Murlasits
- Szilvia Török
- Amin Al-awar
- Zoltán Baráth
- Anikó Pósa
- Csaba Varga
- Erschienen in
- Inflammopharmacology | Ausgabe 2/2018
Abstract
Hydrogen sulfide (H2S) is an endogenous mediator that contributes to many important physiological processes including vasodilation and vascular smooth muscle relaxation; in turn, preventing tissue damage and reducing inflammation. Heme oxygenase (HO) enzymes, of which HO-1 is inducible by harmful stimuli, were found to regulate intestinal inflammation in experimental animal models of colitis. We aimed to investigate the protective effects of H2S against 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in rats, and whether HO enzyme system is involved in the H2S-induced colonic cytoprotection. Male Wistar rats were treated with TNBS to induce colitis, and H2S donor (Lawesson’s reagent) was prepared two times/day at different concentrations, and delivered per os (from day 1 to day 3). Our results suggest that daily treatment (2 times/day) with H2S donor, could significantly decrease the extent of colonic inflammation compared to vehicle treatment, and the most effective daily dose of H2S donor against inflammation was 18.75 µM/kg/day. Per os administration of H2S donor increased the colonic HO enzyme activity; on the contrary, the protective effect of H2S was abolished by the co-treatment with HO inhibitor. Our findings suggest that H2S confers colonoprotection, probably by modulation of anti-inflammatory parameters and HO enzyme activity.
Anzeige
- Titel
- H2S confers colonoprotection against TNBS-induced colitis by HO-1 upregulation in rats
- Verfasst von
-
Krisztina Kupai
Nikoletta Almási
Magdolna Kósa
János Nemcsók
Zsolt Murlasits
Szilvia Török
Amin Al-awar
Zoltán Baráth
Anikó Pósa
Csaba Varga
- Publikationsdatum
- 02.08.2017
- Verlag
- Springer International Publishing
- Erschienen in
-
Inflammopharmacology / Ausgabe 2/2018
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608 - DOI
- https://doi.org/10.1007/s10787-017-0382-8
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.